Type 1 Diabetes Clinical Trial
Official title:
New Strategies for Automated Glycaemic Control: the Issue of Continuous Glucose Monitoring Accuracy Under Hypoglycaemic Conditions
Achieving near-normoglycaemia has been established as the main objective for most patients
with diabetes. However, it is well known that intensification of treatment is associated
with an increase in the frequency of hypoglycemia, especially in the context of insulin
therapy. The burden of hypoglycemia in terms of psychological implications, morbidity and
even mortality, explains why it has been defined as the main limiting factor to achievement
of good metabolic control.
Continuous subcutaneous glucose monitoring (CGM) devices have been claimed to be useful in
hypoglycemia detection/prevention, allowing theoretically for safer intensification of
therapy in diabetic patients. However, accuracy of CGM devices, especially in the
hypoglycemic range, raises some concerns. In fact, commercially available CGM devices
estimate plasma glucose from measurements in the interstitial fluid and not in plasma.
However, the relationship between plasma and interstitial glucose is not fully understood,
especially under dynamic conditions, and this may explain the poor CGM performance during
rapid changes in blood glucose and hypoglycemia.
In this project, the relationship between plasma and interstitial glucose will be evaluated
under conditions of normal glucose concentrations and hypoglycemia. Experiments will be
performed to assess the role, if any, of different plasma insulin concentrations on the
accuracy of CGM.
All the information obtained may be relevant to the improvement of the ability of CGM
devices to detect hypoglycemia and hypoglycemic risk.
Status | Completed |
Enrollment | 14 |
Est. completion date | October 2012 |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Subjects with type 1 diabetes mellitus meeting all of the following criteria will be considered for admission to the study: - Aged between 18 and 60 years - Under CSII or MDI treatment for at least six months before Visit 1 - Body mass index of between 18 and 30 kg/m2 - HbA1c 6.0-8.5% at Visit 1 - Normal laboratory values, ECG, and vital signs unless the investigator considered an abnormality to be clinically irrelevant - Women postmenopausal or using contraception judged by the investigator to be adequate (e.g., oral contraceptives, intra-uterine device or surgical treatment) Exclusion Criteria: - Subjects meeting any of the following criteria will not be included in the study: - Pregnancy and lactation - History of hypersensitivity to the study medications or to drugs with similar chemical structures - Confirmed hypoglycaemia unawareness - Progressive fatal diseases - History of drug or alcohol abuse - History of positive HIV or hepatitis B or C test - Impaired hepatic function, as shown by, but not limited to, SGPT or SGOT of more than twice the upper limit of the normal range at visit 1 - Impaired renal function, as shown by, but not limited to, serum creatinine > 1.5 mg/dL at visit 1 - Clinically relevant microvascular, cardiovascular, hepatic, neurologic, endocrine or other major systemic diseases other than T1DM which could hinder implementation of the clinical study protocol or interpretation of the study results - Pre-planned surgery during the study - Blood donation of more than 500 ml during the past three months for men, or during the past six months for women - Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study - Subject unlikely to comply with clinical study protocol, e.g., uncooperative attitude, inability to return for follow-up visits, or poor likelihood of completing the study - Receipt of an experimental drug or use of an experimental device during the past 30 days. |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Spain | Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario de Valencia | Valencia |
Lead Sponsor | Collaborator |
---|---|
Fundación para la Investigación del Hospital Clínico de Valencia | Universidad Politécnica de Valencia |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Normalized current signal from the CGM devices | CGM devices are electrochemical sensors. Currently available sensors are placed in the subcutaneous tissue where they react with the glucose of the interstitial fluid giving a current signal (in nano Amperes), which is proportional to glucose concentrations. The current signal is then filtered and transformed into plasma glucose estimations through a calibration algorithm built into the CGM device. In this study we will analyze the current signal from CGM obtained under two different experimental conditions: Eu-hypoglycemic clamp with High plasma insulin concentrations Eu-hypoglycemic clamp with relatively Low plasma insulin concentrations This will allow for establishing the role, if any, of different plasma insulin concentrations on the accuracy of CGM to identify plasma glucose falls resulting in hypoglycaemia. Since CGM sensors can exhibit different sensitivities to glucose concentrations, the current signal will be normalized before statistical analysis |
330 minutes | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 |